XOMA Royalty (XOMA) Operating Income Growth (3y) (2014 - 2026)
XOMA Royalty (XOMA) Operating Income Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | 69.02% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 55.96% |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 63.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.86% |
| Dec 31, 2025 | 32.98% |
| Jun 30, 2025 | 43.67% |
| Mar 31, 2025 | 69.52% |
| Dec 31, 2024 | -30.82% |
| Sep 30, 2024 | -67.22% |
| Jun 30, 2024 | -48.72% |
| Mar 31, 2024 | -2.91% |
| Dec 31, 2023 | -41.53% |
| Sep 30, 2023 | -29.11% |
| Jun 30, 2023 | -23.65% |
| Mar 31, 2023 | -21.89% |
| Dec 31, 2022 | -15.78% |
| Sep 30, 2022 | -52.01% |
| Jun 30, 2022 | -0.39% |
| Mar 31, 2022 | -45.28% |
| Dec 31, 2021 | 121.54% |
| Sep 30, 2021 | 14.26% |
| Jun 30, 2021 | -0.81% |
| Mar 31, 2021 | -7.75% |